Table 1.

Olaparib: Background Information

Variables	Information
Chemical name	4‐[(3‐{[4‐(cyclopropylcarbonyl) piperazin‐1‐yl]carbonyl}‐4‐fluorophenyl)methyl]phthalazin‐1 (2H)‐one
Mechanism of action	Olaparib is an inhibitor of PARP enzymes, including PARP1, PARP2, and PARP3.
Other approvals	December 19, 2014: As monotherapy in patients with deleterious or suspected deleterious germline BRCA‐mutated advanced ovarian cancer that have been treated with three or more prior lines of chemotherapy. August 17, 2017: As monotherapy for the maintenance treatment of adult patients recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum‐based chemotherapy. January 12, 2018: As monotherapy for the treatment of adult patients with gBRCAm HER2‐negative metastatic breast cancer who have previously been treated with chemotherapy. These patients could have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. December 27, 2019: As monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first‐line platinum‐based chemotherapy regimen. May 19, 2020: As monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene‐mutated mCRPC who have progressed after prior treatment with enzalutamide or abiraterone.

Abbreviations: FDA, U.S. Food and Drug Administration; gBRCAm, BRCA mutated in the germline; HRR, homologous recombination repair; mCRPC, metastatic castration‐resistant prostate cancer; PARP, poly (ADP‐ribose) polymerase.